Serious Adverse Cutaneous and Hepatic Toxicities Associated with Nevirapine Use by Non-HIV-Infected Individuals

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 2, 2004, Pages 120-125

  Patel, Shilpa M ^b   Johnson, Stuart ^e   Belknap, Steven M ^b   Chan, Juliana ^c   Sha, Beverly E ^d   Bennett, Charles ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d RUSH MEDICAL COLLEGE   (United States)

^e LOYOLA UNIVERSITY CHICAGO   (United States)

Author keywords

AIDS; Drug reaction liver; Drug reaction skin; Hepatitis; Hepatotoxicity; HIV; Hypersensitivity reaction; Nevirapine; Postexposure prophylaxis; Postmarketing drug surveillance

Indexed keywords

CORTICOSTEROID; DIDANOSINE; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; CLINICAL FEATURE; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; EOSINOPHILIA; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HEALTH CARE PERSONNEL; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERSENSITIVITY REACTION; LABORATORY PERSONNEL; LIVER BIOPSY; LIVER NECROSIS; LIVER TOXICITY; LIVER TRANSPLANTATION; LYMPHOCYTE COUNT; MALE; NEEDLESTICK INJURY; NORMAL HUMAN; NURSE; PHYSICIAN; PRIORITY JOURNAL; PROPHYLAXIS; RASH; RHABDOMYOLYSIS; SEXUAL INTERCOURSE; SKIN TOXICITY; STEVENS JOHNSON SYNDROME; VOLUNTEER;

EID: 1642540100     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200402010-00003     Document Type: Article

References (32)

1. Murphy RL. Non-nucleoside reverse transcriptase inhibitors. AIDS Clin Care. 1997;9:75-79.
2. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses. 1992;8:119-134.
3. Lamson MJ, Sabo JP, MacGregor TR, et al. Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharm Drug Dispos. 1999;20:285-291.
4. Easterbrook PJ, Newson R, Ives N, et al. Comparison of virologic, immunologic, and clinical response to five different initial protease inhibitor-containing and nevirapine-containing regimens. J Acquir Immune Defic Syndr. 2001;27:350-364.
5. Pollard RB, Robinson P, Dransfield K. Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clin Ther. 1998;20:1071-1092.
6. Montaner JS, Hall D, Carlier H, et al. Analyses of four clinical trials to assess the risk of hepatotoxicity with nevirapine: correlation with CD4+ levels, hepatitis B and C seropositivity, and baseline liver function tests. Can J Infect Dis. 2001;12(Suppl B):31B.
7. Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for post-exposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR Wkly Rep. 2001;49:1153-1156.
8. Johnson S, Baraboutis JG. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284:2722-2723.
9. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997-2000. MMWR Wkly Rep. 2001;49:1153-1156.
10. Sha BE, Proia LA, Kessler HA. Adverse effects associated with use of nevirapine in HIV postexposure prophylaxis for 2 health care workers. JAMA. 2000;284:2722-2723.
11. Benn PD, Mercey DE, Brink N, et al. Prophylaxis with a nevirapine-containing triple regimen after exposure to HIV-1. Lancet. 2001;357: 687-688.
12. Leitze Z, Nadeem A, Chodhay A, et al. Nevirapine-induced hepatitis treated with corticosteroids? AIDS. 1998;12:1115-1117.
13. Ziol M, Ganne-Carrie N, Christidis C, et al. Non-alcoholic steatohepatitis in HIV and HCV infected patients treated by antiretroviral tritherapy. J Hepatol. 1999;30(Suppl):S239.
14. Jarrouse B, Cohen P, Berlureua P, et al. Nevirapine-induced fulminant hepatitis: presentation of case and analysis of risk factors. In: Proceedings of the Seventh European Conference on Clinical Aspects and Treatment of HIV Infection. Lisbon, Portugal; 1999:23-27.
15. Cattelan AM, Erne E, Saltino A, et al. Severe hepatic failure related to nevirapine treatment. Clin Infect Dis. 1999;29:455-456.
16. Johnson S, Chan J, Bennett CL. Hepatotoxicity after prophylaxis with a nevirapine containing anti-retroviral regimen. Ann Intern Med. 2002;137: 146-147.
17. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol. 1998;15:246-258.
18. Brinkman K, ter Hofstede HJM, Burger DM, et al. Adverse effects of reverse transcriptase inhibitors: mitochondrial toxicity as common pathway. AIDS. 1998;12:1735-1744.
19. Bissel MD, Gores JG, Laskin DL, et al. Drug-induced liver injury: mechanisms and test systems. Hepatology. 2001;33:1009-1113.
20. Sissoko D, Ajana F, de la Tribonniere X, et al. Cutaneous, hepatic, and hematologic manifestations due to nevirapine: DRESS syndrome? Presse Med. 2000;29:1041-1042.
21. Pilero PJ, Purdy B. Nevirapine-associated hepatitis: a case series and review of the literature. AIDS Reader. 2001;11:379-382.
22. Bundrow D, Rosoff L, Abaloufia DM. Optimal treatment of nevirapine-associated hepatotoxicity remains uncertain. AIDS Reader. 2001;11:577-580.
23. Prendville J, Hebert A, Greenwald M, et al. Management of Stevens-Johnson syndrome and toxic epidermal necrolysis. Lancet. 1998;352: 1586-1589.
24. Leitze Z, Nadeem A, Coudhary A, et al. Nevirapine-associated hepatitis treated with corticosteroids? AIDS. 1998;12:1115-1117.
25. Bourezane Y, Salard D, Hoen B, et al. DRESS (drug rash with eosinophilia and systemic symptoms) syndrome associated with nevirapine therapy. Clin Infect Dis. 1998;27:1321-1322.
26. Harris M, Montaner JSG. Editorial comment: nevirapine hepatotoxicity-an important clinical issue. AIDS Reader. 2001;11:580.
27. Kessler DA. Introducing MedWatch: a new approach to reporting medication and device adverse effects and product problems. JAMA. 1993;269: 2765-2768.
28. Temple R. Meta-analysis and epidemiologic studies in drug development and post-marketing surveillance. JAMA. 1999;281:841-844.
29. Bennett CL, Kiss JE, Weinberg PD, et al. Thrombotic thrombocytopenic purpura after stenting and ticlopidine. Lancet. 1998;352:1036-1037.
30. Montaner JS, Cahn P, Zala C, et al. 1100.1286 Study Team. Randomized, controlled study of the effects of a short course of prednisone on the incidence of rash associated with nevirapine in patients infected with HIV-1. J Acquir Immune Defic Syndr. 2003;33:41-46.
31. Knobel H, Miro JM, Domingo P, et al. Failure of a short-term prednisone regimen to prevent nevirapine-associated rash: a double-blind placebo-controlled trial: the GESIDA 09/99 study. J Acquir Immune Defic Syndr. 2001;28:14-18.
32. Bennett CL, Connors JM, Carwile JM, et al. Thrombotic thrombocytopenic purpura associated with clopidogrel. N Engl J Med. 2000;342:1773-1777.